These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28870953)

  • 1. Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experience.
    Cicero G; Lo Re G; DE Luca R; Vernuccio F; Picone D; Midiri M; Lagalla R
    Anticancer Res; 2017 Sep; 37(9):5187-5192. PubMed ID: 28870953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
    Lucidarme O; Wagner M; Gillard P; Kim S; Bachet JB; Rousseau B; Mazard T; Louvet C; Chibaudel B; Cohen R; Garcia-Larnicol ML; Gobert A; Henriques J; André T
    Cancer Imaging; 2019 Dec; 19(1):85. PubMed ID: 31818317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody.
    Li L; Xu Y; Yang Y; Ye F; Zhang H; Zhou A; Zhao X
    Eur J Radiol; 2021 Aug; 141():109823. PubMed ID: 34146911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
    Abramson RG; Lakomkin N; Hainline A; Kang H; Hutson MS; Arteaga CL
    AJR Am J Roentgenol; 2018 Jan; 210(1):W1-W7. PubMed ID: 29064750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.
    Reginelli A; Clemente A; Cardone C; Urraro F; Izzo A; Martinelli E; Troiani T; Ciardiello F; Brunese L; Cappabianca S
    Future Oncol; 2018 Dec; 14(28):2905-2913. PubMed ID: 29433345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor response and clinical outcome in metastatic gastrointestinal stromal tumors under sunitinib therapy: comparison of RECIST, Choi and volumetric criteria.
    Schramm N; Englhart E; Schlemmer M; Hittinger M; Übleis C; Becker CR; Reiser MF; Berger F
    Eur J Radiol; 2013 Jun; 82(6):951-8. PubMed ID: 23518148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
    Granata V; Fusco R; Catalano O; Filice S; Amato DM; Nasti G; Avallone A; Izzo F; Petrillo A
    PLoS One; 2015; 10(11):e0142876. PubMed ID: 26566221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.
    Brufau BP; Cerqueda CS; Villalba LB; Izquierdo RS; González BM; Molina CN
    Radiographics; 2013 Oct; 33(6):1691-716. PubMed ID: 24108558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.
    Uhrig M; Hassel JC; Schlemmer HP; Ganten MK
    Acad Radiol; 2013 Apr; 20(4):423-9. PubMed ID: 23498982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.
    Seyal AR; Parekh K; Arslanoglu A; Gonzalez-Guindalini FD; Tochetto SM; Velichko YS; Yaghmai V
    Abdom Imaging; 2015 Oct; 40(8):3043-51. PubMed ID: 26353898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
    Liu K; Li G; Fan C; Zhou C; Li J
    Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer.
    Jang HJ; Kim BC; Kim HS; Kim JH; Song HH; Kim JB; Park JJ; Yoon SN; Woo JY; Zang DY
    Oncology; 2014; 86(2):117-21. PubMed ID: 24480800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
    Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
    Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
    Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
    Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.